You are here:

  1. Home
  2. NICE Guidance
  3. Population groups
  4. Children and teenagers

Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

  • Highly specialised technologies guidance
  • Reference number: HST20
  • Published:  05 May 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final evaluation determination
  2. Evaluation consultation: 1
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

History

A list of downloadable documents created during development.

Final evaluation determination

  • Final evaluation determination

  • Final evaluation determination document (PDF 295 KB)

    Published:
    01 April 2022
  • Public committee slides (PDF 1.08 MB)

    Published:
    01 April 2022
  • Committee papers (PDF 1.47 MB)

    Published:
    01 April 2022

Evaluation consultation: 1

  • Evaluation consultation: 1

  • Evaluation consultation document (PDF 282 KB)

    Published:
    02 December 2021
  • Committee papers (PDF 4.86 MB)

    Published:
    02 December 2021
  • Public committee slides November 2021 (PDF 1.41 MB)

    Published:
    02 December 2021
  • Evaluation consultation document (Online commenting)

Invitation to participate

  • Equality impact assessment (Scoping) (PDF 129 KB)

    Published:
    15 June 2021
  • Final scope (PDF 200 KB)

    Published:
    15 June 2021
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 293 KB)

    Published:
    15 June 2021
  • Final stakeholder list (PDF 186 KB)

    Published:
    15 June 2021

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Draft matrix post referral (PDF 184 KB)

    Published:
    15 June 2021
  • Draft scope post referral (PDF 232 KB)

    Published:
    15 June 2021
Back to top